

Double-blind peer review submissions: write DBPR and your manuscript number here

Corresponding author(s): Thomas Kun

Last updated by author(s): Feb 19, 2020

Reporting Summary

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics						
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a Confirmed						
☐ ☐ The exact sam	pple size (n) for each experimental group/condition, given as a discrete number and unit of measurement					
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly					
The statistical Only common to	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
A description	A description of all covariates tested					
A description	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
A full descript AND variation	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable.						
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings						
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated						
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and code						
Policy information about <u>availability of computer code</u>						
Data collection	ImageJ 1.50b (open source), µManager 1.4.22 (open source), Microscope Control (custom code: C:\Users\3dstorm\git\MicroscopyControl2), Experiment Editor (custom code: C:\Users\3dstorm\git\MicroscopyControl2), Chronos 4.8.0 (commercial)					
Data analysis	rapidSTORM 3 (open source), Post Processing Software (custom code), ImageJ 1.50b (open source) with custom-written plugins, Matlab R2018b (commercial) with custom-written scripts, Excel 2013 (commercial), GraphPad Prism 5 (commercial), ViSP v1.0 (open source)					
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.						
Data						
- Accession codes, un - A list of figures that	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability					
All raw and processed data will be made available upon request.						
Field-specific reporting						

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

Life sciences study design

All studies must disclose on these points even when the o	disclosure is negative.
---	-------------------------

an stadies mast disclose on these points even when the disclosure is negative

Sample size

The multiplex experiment on U2OS cells was designed to prove the feasability of the re-STORM approach. Here, no sample size determination was done. Multiplex experiments on tissue samples were used to analyse protein distribution. Therefore, quantifications were performed on 3 calyces of Held per experiment with at least 3 experiments (up to 5 experiments). For the analysis of the overall synaptic distribution, data were collected from 4-16 line profiles per calyx. For the AZ-specific analysis, 2 AZ-positive and 2-AZ-negative regions were analyzed per calyx. For detailed sample numbers, see Supplementary Table 5.

For detailed sample numbers, see Supplementary Table :

Data exclusions No data from samples that passed our requirement were excluded from analyses.

Replication Every

Every antibody and other labeling agent used for our multiplex experiments was successfully and reproducibly pretested in individual experiments.

Randomization

All calyx segments that passed our demands for a contigous membrane and AZ staining were analyzed equally, and thus, there was no requirement for randomization.

Blinding

Acquisition and quantification were performed fully automatically. Therefore, there was no need for blinding.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	n/a Involved in the study		Involved in the study
	Antibodies	\boxtimes	ChIP-seq
	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology	\boxtimes	MRI-based neuroimaging
	Animals and other organisms		
\boxtimes	Human research participants		
\boxtimes	Clinical data		
	All the second s		

Antibodies

Antibodies used

See Supplementary Table 3.

Validation

See Supplementary Table 3.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

The U2OS (human) cell-line were obtained from M. Heilemann laboratory; Initially from CLS Cell Line. Services, Eppelheim, Germany

Authentication

U2OS cells were not authentified. As constititutive expression of Nup133-Ypet was present in all cells observed, post-hoc contamination by other cell lines can be excluded.

Mycoplasma contamination

U2OS cells were tested negative for mycoplasma contamination at the source laboratory.

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals Sprague-Dawley wild-type rats, Charles River, 12 days old, sex was not determined

Wild animals

This study did not involve wild animals.

Field-collected samples

This study did not involve field-collected samples.

Ethics oversight

All experiments were conducted in accordance with the European and German animal welfare guidelines, and approved by the Regierungspraesidium Karlsruhe (protocol G-75/15).

Note that full information on the approval of the study protocol must also be provided in the manuscript.